Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- PM Kishida Vows to Move Up Booster, Offer COVID-19 Pill as Japan Girds for Omicron
December 20, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- LDP Study Group Proposal Calls for 2%-Plus Adjustment Rate for 2022 Drug Price Revision
December 16, 2021
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
- Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
- Doctor, Pharmacist Reps Call for Expanding Fees for Biosimilars: Chuikyo
December 13, 2021
- LDP Project Team to Compile Proposal to Move Up Booster Interval
December 13, 2021
- METI to Dole Out Support for “Dual-Use” Production Bases to Boost Pandemic Preparedness
December 13, 2021
- Sakigake Status Withdrawn for Takeda’s Pevonedistat: MHLW
December 10, 2021
- Fiscal Discipline for Drug Spending Could Be Discussed towards FY2023: MOF Budget Examiner
December 10, 2021
- E Keppra Generics from 12 Firms to Join NHI Price List, Patanol and Velcade AGs Too
December 9, 2021
- Payers Want Low-Generic Fee Cuts Applied to Medical Institutions Too: Chuikyo
December 9, 2021
- No Chuikyo Members Call for Formulary Incentives under Medical Fee Schedule
December 9, 2021
- Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
- MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…